Immunomedics Inc

Immunomedics was founded in 1982 and is headquartered in Morris Plains, New Jersey. This clinical stage biopharmaceutical company develops monoclonal antibody-based products meant for treating cancer and other serious diseases. In 2019, the Company announced a clinical collaboration with Roche to evaluate the safety and efficacy of combining their products as a frontline treatment of patients with metastatic or inoperable locally advanced triple-negative breast cancer. Also in 2019, Immunomedics reported a collaboration with GBG to develop a potential treatment for patients with a specific type of breast cancer in the curative setting. In 2020, Immunomedics announced that the US Food and Drug Administration (FDA) had accepted the company’s Biologics License Application (BLA) for filing. The company’s application seeks accelerated approval of solutions for the treatment of patients with metastatic triple-negative breast cancer. As of September 30, 2019, the company reported that it had $369.2 million in cash, cash equivalents, and marketable securities. Interested in trading this instrument? Follow it for news and updates on the current IMMU value.